9th Feb 2015 07:50
LONDON (Alliance News) - Quantum Pharma PLC on Monday said it expects to beat market expectations for its full year, as it gained market share in its core market.
The niche pharmaceutical sector supplier said it made progress across its business in the financial year to the end of January and expects its adjusted earnings before interest, taxation, depreciation and amortisation and its pretax profit to be "comfortably ahead" of market expectations for the year.
The group's Quantum Pharmaceutical core business increased its customer base across the year and won a major three-year supply deal in December from Bestway Panacea Healthcare Ltd, it said.
Its Colonis specialist pharmaceutical product development business also reached a milestone during the year with the launch of its Aviticol capsules, its first licensed medicine.
"This has been a transformational year for Quantum with good progress made across all areas of the group and Colonis reaching a very significant milestone with the launch of its first licensed medicine," said Quantum Chief Executive Officer Andrew Scaife.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Quantum Pharma